WebJan 6, 2024 · ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor: Currently being developing as a potential treatment for moderate to severe atopic … WebJanuary 06, 2024. Aclaris Therapeutics Provides 2024 Outlook (GlobeNewswire) - "Atopic Dermatitis (ATI-1777-AD-202): This Phase 2b trial to determine the efficacy, safety, …
Aclaris Therapeutics Provides 2024 Outlook - TipRanks.com
WebDec 14, 2024 · Aclaris ATI-1777-AD-202. eCOA. 10+ Downloads. Everyone. info. Install. Add to wishlist. About this app. arrow_forward. The Aclaris eCOA App is intended for use … WebMar 9, 2024 · ATI-450-RA-202 is the rheumatoid arthritis program, ... The ATI-1777-AD-202 program is in a Phase IIb trial that is projected to produce topline data around the middle … cc plaza 2
Aclaris Therapeutics Announces Positive Preliminary Topline …
WebJan 10, 2024 · ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor: Currently being developing as a potential treatment for moderate to severe atopic … WebMar 7, 2024 · ATI 1777 is a topically available small molecule, soft Janus kinase 1 and 3 (JAK1 and JAK3) inhibitor, being developed by Aclaris Therapeutics, after ATI 1777 - … cc plaza nueva